News

Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...
Zacks Investment Research on MSN2d
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on two blood-cancer drugs — Imbruvica and Venclexta — it has since built a ...
TipRanks on MSN5d
The Week That Was, The Week Ahead: Macro & Markets, July 13, 2025
Everything to Know about Macro and Markets Stock indexes fell on Friday, reversing mid‑week gains and closing in the red, as the tariff theme came ...